



# Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

## ESPS Peer-review Report

**Name of Journal:** World Journal of Hepatology

**ESPS Manuscript NO:** 6767

**Title:** An update on Inflammatory Bowel Disease in patients with Primary Sclerosing Cholangitis

**Reviewer code:** 00049305

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-10-30 09:35

**Date reviewed:** 2013-12-08 18:55

| CLASSIFICATION  | LANGUAGE EVALUATION  | RECOMMENDATION                      | CONCLUSION  |
|---|--|-------------------------------------|---|
| <input type="checkbox"/> Grade A (Excellent)            | <input checked="" type="checkbox"/> Grade A: Priority Publishing     | Google Search:                      | <input type="checkbox"/> Accept                                   |
| <input checked="" type="checkbox"/> Grade B (Very good) | <input type="checkbox"/> Grade B: minor language polishing           | <input type="checkbox"/> Existed    | <input checked="" type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C (Good)                 | <input type="checkbox"/> Grade C: a great deal of language polishing | <input type="checkbox"/> No records | <input type="checkbox"/> Rejection                                |
| <input type="checkbox"/> Grade D (Fair)                 | <input type="checkbox"/> Grade D: rejected                           | <input type="checkbox"/> Existed    | <input type="checkbox"/> Minor revision                           |
| <input type="checkbox"/> Grade E (Poor)                 |  | <input type="checkbox"/> No records | <input type="checkbox"/> Major revision                           |

## COMMENTS TO AUTHORS

In this review paper, Dr. Tsaitas, et al. described the clinical and molecular characteristics of PSC complicated by IBD. It presented the detailed information on the prevalence of this kind disorder, strategies for surveillance and treatment. 1, Please describe the genetic susceptibility of two kinds of disorders. 2, Please describe immuno-pathogenic links between two diseases. 3, In last sentence of Abstract, the authors mentioned the dose of UDCA at low doses (8-15 mg/dl) and high doses (15-30 mg/dl). Please check "mg/dl", it it correct? 4, Please describe how to differentially diagnose.